Department of Respiratory and Critical Care Medicine, The First College of Clinical Medicine Science, China Three Gorges University, Yichang, 443003, People's Republic of China.
Department of Respiratory and Critical Care Medicine, Yichang Central People's Hospital at Zhijiang, NO. 183 Yiling Road, Zhijiang, 443003, People's Republic of China.
BMC Geriatr. 2022 Aug 24;22(1):703. doi: 10.1186/s12877-022-03394-9.
Sarcopenia is listed as a treatment trait in behavioral/risk factors for severe asthma, but studies on asthma and sarcopenia are lacking. This study aimed to determine the associations between sarcopenia with asthmatic prevalence, symptoms, lung function and comorbidities.
Fifteen thousand four hundred four individuals from the China Health and Retirement Longitudinal Study(CHARLS) and 10,263 individuals from the Study on global AGEing and adult health(SAGE) in China were included in this study. Four components of this study were used to assess the bidirectional association in the prevalence between sarcopenia with asthma, and estimate the relationships between sarcopenia with asthmatic symptoms, lung function and comorbidities via generalized additive models. The 10-item Center for Epidemiological Studies-Depression Scale ≥ 12 scores was classified as depression.
In the CHARLS and SAGE, the prevalence of sarcopenia in asthmatics was higher than those without asthma. Asthmatics with sarcopenia had a significantly increased prevalence of severe shortness of breath(sarcopenia yes vs. no, adjusted OR = 3.71, 95%CI: 1.43-9.60) and airway obstruction in the SAGE(sarcopenia yes vs. no, adjusted OR = 6.82, 95%CI: 2.54-18.34) and an obvious reduction of PEF in the CHARLS and SAGE(sarcopenia yes vs. no, adjusted RR = 0.86, 95%CI: 0.82-0.91) compared to asthmatics without sarcopenia. The presence of sarcopenia was positively associated with the prevalence of chronic obstructive pulmonary disease(sarcopenia yes vs no, adjusted OR = 5.76, 95%CI:2.01-16.5) and depression(sarcopenia yes vs no, adjusted OR = 1.87, 95%CI:1.11-3.14) in asthmatics.
Our findings indicated that sarcopenia partakes in the development of asthma by affecting lung function and comorbidities and maybe considered a treatable trait of asthma management.
肌少症被列为严重哮喘行为/危险因素的治疗特征，但关于哮喘和肌少症的研究却很少。本研究旨在确定肌少症与哮喘患病率、症状、肺功能和合并症之间的关系。
本研究纳入了中国健康与退休纵向研究（CHARLS）的 15404 人和中国全球老龄化与成人健康研究（SAGE）的 10263 人。本研究的四个部分用于评估肌少症与哮喘之间的双向关联，并通过广义加性模型估计肌少症与哮喘症状、肺功能和合并症之间的关系。10 项流行病学研究中心抑郁量表评分≥12 分被归类为抑郁。
在 CHARLS 和 SAGE 中，哮喘患者的肌少症患病率高于无哮喘患者。患有肌少症的哮喘患者发生严重呼吸困难的患病率显著增加（肌少症阳性与无肌少症相比，调整后的 OR=3.71，95%CI：1.43-9.60），SAGE 中气道阻塞也显著增加（肌少症阳性与无肌少症相比，调整后的 OR=6.82，95%CI：2.54-18.34），且 CHARLS 和 SAGE 中 PEF 明显降低（肌少症阳性与无肌少症相比，调整后的 RR=0.86，95%CI：0.82-0.91）。与无肌少症的哮喘患者相比，肌少症的存在与慢性阻塞性肺疾病（肌少症阳性与无肌少症相比，调整后的 OR=5.76，95%CI：2.01-16.5）和抑郁（肌少症阳性与无肌少症相比，调整后的 OR=1.87，95%CI：1.11-3.14）的患病率呈正相关。
我们的研究结果表明，肌少症通过影响肺功能和合并症参与哮喘的发生发展，可能被视为哮喘管理的一种可治疗特征。
